• Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Repligen Corp

+ Add to Watchlist

RGEN:US

19.5250 USD 0.0450 0.23%

As of 15:01:42 ET on 09/18/2014.

Snapshot for Repligen Corp (RGEN)

Open: 19.7200 Day's Range: 19.4300 - 19.8800 Volume: 211,379
Previous Close: 19.5700 52wk Range: 9.8400 - 24.6800 1-Yr Rtn: +91.48%

Stock Chart for RGEN

No chart data available.
  • RGEN:US 19.5200
  • 1D
  • 1M
  • 1Y
19.5700
Interactive RGEN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for RGEN

Current P/E Ratio (ttm) 40.5659
Estimated P/E(12/2014) 73.2959
Relative P/E vs. SPX 2.2412
Earnings Per Share (USD) (ttm) 0.4824
Est. EPS (USD) (12/2014) 0.2670
Est. PEG Ratio -
Market Cap (M USD) 638.92
Shares Outstanding (M) 32.65
30 Day Average Volume 364,072
Price/Book (mrq) 5.5250
Price/Sale (ttm) 9.8212
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 11/07/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for RGEN

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for RGEN

Repligen Corporation is a biotechnology company. The Company develops therapeutics for the treatment of diseases of the central nervous system. Repligen owns owns intellectual property on monoclonal antibody and antibody fusion products.

Walter C HerlihyPresident/CEO/TreasurerJon K SnodgresChief Financial Officer
Tony J HuntChief Operating OfficerJames R RuscheSenior VP:Research & Dev
More Company Profile & Key Executives for RGEN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil